Featured Publications
Dichloroacetate as a novel pharmaceutical treatment for cancer-related fatigue in melanoma
Zhang X, Lee W, Leitner B, Zhu W, Fosam A, Li Z, Gaspar R, Halberstam A, Robles B, Rabinowitz J, Perry R. Dichloroacetate as a novel pharmaceutical treatment for cancer-related fatigue in melanoma. AJP Endocrinology And Metabolism 2023, 325: e363-e375. PMID: 37646579, PMCID: PMC10642987, DOI: 10.1152/ajpendo.00105.2023.Peer-Reviewed Original ResearchConceptsCancer-related fatigueNovel pharmaceutical treatmentsPhysical functionPharmaceutical treatmentTumor growthCancer treatmentStandard cancer treatmentTumor-bearing miceLate-stage tumorsEffective pharmaceutical treatmentMurine cancer modelsNew metabolic targetsMultiple cancer typesAdjuvant therapyCommon complicationPatients' qualitySymptom managementClinical trialsMurine modelPotential therapyPharmaceutical therapySmall molecule inhibitorsCancer modelDCA treatmentLactate concentration
2024
Metabolic underpinnings of cancer-related fatigue
Zhang X, Perry R. Metabolic underpinnings of cancer-related fatigue. AJP Endocrinology And Metabolism 2024, 326: e290-e307. PMID: 38294698, DOI: 10.1152/ajpendo.00378.2023.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCancer-related fatigueMechanisms of cancer-related fatigueInsulin resistanceImpact of obesityCancer-induced painComplication of cancerTarget obesityInduce chronic inflammationObesityNarrative reviewObesity/insulin resistanceTumor growthChronic inflammationDetrimental complicationsCancer patientsMetabolic alterationsClinical researchNeuroendocrinological disturbancesMetabolic underpinningsAnalyzed recent studiesInsulinFatigueBehavioral disruptionPatientsPotential mechanisms
2019
SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia
Nasiri AR, Rodrigues MR, Li Z, Leitner BP, Perry RJ. SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia. Cancer & Metabolism 2019, 7: 10. PMID: 31867105, PMCID: PMC6907191, DOI: 10.1186/s40170-019-0203-1.Peer-Reviewed Original ResearchControlled-release mitochondrial protonophoreInsulin-lowering agentsTumor growthSodium-glucose cotransporter 2 inhibitorsObesity-cancer connectionSustained weight lossCotransporter 2 inhibitorsObesity-associated cancersSubcutaneous insulin infusionInsulin-lowering effectTumor glucose uptakeBreast tumor growthMultiple comparisonsMultiple tumor typesSGLT2 inhibitionSGLT2 inhibitorsObese miceInsulin infusionColon cancer progressionTherapeutic approachesMouse modelBonferroni multiple comparisonsGlucose metabolismColon cancerHyperinsulinemia
2018
Uncoupling Hepatic Oxidative Phosphorylation Reduces Tumor Growth in Two Murine Models of Colon Cancer
Wang Y, Nasiri AR, Damsky WE, Perry CJ, Zhang XM, Rabin-Court A, Pollak MN, Shulman GI, Perry RJ. Uncoupling Hepatic Oxidative Phosphorylation Reduces Tumor Growth in Two Murine Models of Colon Cancer. Cell Reports 2018, 24: 47-55. PMID: 29972790, PMCID: PMC6056247, DOI: 10.1016/j.celrep.2018.06.008.Peer-Reviewed Original ResearchConceptsControlled-release mitochondrial protonophoreTumor growthGlucose uptakeDiet-induced obesityMurine colon cancer modelColon cancer modelHepatic energy metabolismColon cancer pathogenesisHormonal milieuPlasma insulinFed miceInsulin infusionMurine modelColon cancerCancer modelCancer pathogenesisOxidative phosphorylationNeoplastic growthMitochondrial protonophoreHepatic oxidative phosphorylationObesityUnderlying mechanismEnergy metabolismCancerInsulin